Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease

Seminars in Cancer Biology

Volumn 23, Issue 6 PB, 2013, Pages 471-482

  Tian, Yuan ^a   Wong, Vincent Wai Sun ^a   Chan, Henry Lik Yuen ^a   Cheng, Alfred Sze Lok ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chromatin modifications; Epigenetics; Hepatocellular carcinoma; Insulin resistance; Non alcoholic steatohepatitis

Indexed keywords

ANDROGEN RECEPTOR; DNA METHYLTRANSFERASE; E1A ASSOCIATED P300 PROTEIN; ESTROGEN RECEPTOR; GLUCOSE; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 3; INSULIN; LIPID; MICRORNA; MICRORNA 122; MICRORNA 143; MICRORNA 155; MICRORNA 21; MICRORNA 23A; SEX HORMONE; SIRTUIN 1; SIRTUIN 6; UNCLASSIFIED DRUG;

CHROMATIN; DEACETYLATION; DIABETES MELLITUS; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GENETIC REGULATION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; LIVER CELL CARCINOMA; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PREVALENCE; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; RNA INTERFERENCE; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

CHROMATIN MODIFICATIONS; EPIGENETICS; HEPATOCELLULAR CARCINOMA; INSULIN RESISTANCE; NON-ALCOHOLIC STEATOHEPATITIS;

CARCINOMA, HEPATOCELLULAR; EPIGENESIS, GENETIC; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; SEX FACTORS; SIGNAL TRANSDUCTION;

EID: 84887613357     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.08.010     Document Type: Review

References (232)

1. Villanueva A., Hernandez-Gea V., Llovet J.M. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013, 10:34-42.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
3. Welzel T.M., Graubard B.I., Quraishi S., Zeuzem S., Davila J.A., El-Serag H.B., et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013, 108:1314-1321.
4. Yuen M.F., Tanaka Y., Fong D.Y., Fung J., Wong D.K., Yuen J.C., et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009, 50:80-88.
5. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
6. El-Serag H.B. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004, 127:S27-S34.
7. Larter C.Z., Chitturi S., Heydet D., Farrell G.C. A fresh look at NASH pathogenesis, Part 1: the metabolic movers. J Gastroenterol Hepatol 2010, 25:672-690.
8. Farrell G.C., van Rooyen D., Gan L., Chitturi S. NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver 2012, 6:149-171.
9. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
10. Bhala N., Angulo P., van der Poorten D., Lee E., Hui J.M., Saracco G., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54:1208-1216.
11. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011, 11:726-734.
12. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
13. Huang J., Deng Q., Wang Q., Li K.Y., Dai J.H., Li N., et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet 2012, 44:1117-1121.
14. Guichard C., Amaddeo G., Imbeaud S., Ladeiro Y., Pelletier L., Maad I.B., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012, 44:694-698.
15. Fujimoto A., Totoki Y., Abe T., Boroevich K.A., Hosoda F., Nguyen H.H., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012, 44:760-764.
16. You J.S., Jones P.A. Cancer genetics and epigenetics: two sides of the same coin. Cancer Cell 2012, 22:9-20.
17. Zhang Z. Genomic landscape of liver cancer. Nat Genet 2012, 44:1075-1077.
18. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011, 17:330-339.
19. Katada S., Imhof A., Sassone-Corsi P. Connecting threads: epigenetics and metabolism. Cell 2012, 148:24-28.
20. Kaelin W.G., McKnight S.L. Influence of metabolism on epigenetics and disease. Cell 2013, 153:56-69.
21. Sassone-Corsi P. Physiology: when metabolism and epigenetics converge. Science 2013, 339:148-150.
22. Dang C.V. Links between metabolism and cancer. Genes Dev 2012, 26:877-890.
23. Lu C., Thompson C.B. Metabolic regulation of epigenetics. Cell Metab 2012, 16:9-17.
24. Yeh S.H., Chen P.J. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology 2010, 78(Suppl 1):172-179.
25. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273. e1.
26. Williams C.D., Stengel J., Asike M.I., Torres D.M., Shaw J., Contreras M., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011, 140:124-131.
27. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
28. Wong V.W., Chu W.C., Wong G.L., Chan R.S., Chim A.M., Ong A., et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012, 61:409-415.
29. Dixon M.F., Neville P.M., Mapstone N.P., Moayyedi P., Axon A.T. Bile reflux gastritis and Barrett's oesophagus: further evidence of a role for duodenogastro-oesophageal reflux. Gut 2001, 49:359-363.
30. Targher G., Bertolini L., Rodella S., Tessari R., Zenari L., Lippi G., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diab Care 2007, 30:2119-2121.
31. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
32. Wong V.W., Wong G.L., Choi P.C., Chan A.W., Li M.K., Chan H.Y., et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010, 59:969-974.
33. Klain J., Fraser D., Goldstein J., Peiser J., Avinoah E., Ovnat A., et al. Liver histology abnormalities in the morbidly obese. Hepatology 1989, 10:873-876.
34. Charlton M.R., Burns J.M., Pedersen R.A., Watt K.D., Heimbach J.K., Dierkhising R.A. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141:1249-1253.
35. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-1350.
36. Wong V.W., Wong G.L., Yip G.W., Lo A.O., Limquiaco J., Chu W.C., et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011, 60:1721-1727.
37. Poonawala A., Nair S.P., Thuluvath P.J. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000, 32:689-692.
38. Struben V.M., Hespenheide E.E., Caldwell S.H. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000, 108:9-13.
39. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
40. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
41. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
42. Rafiq N., Bai C., Fang Y., Srishord M., McCullough A., Gramlich T., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7:234-238.
43. Kawamura Y., Arase Y., Ikeda K., Seko Y., Imai N., Hosaka T., et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012, 107:253-261.
44. Lazo M., Hernaez R., Bonekamp S., Kamel I.R., Brancati F.L., Guallar E., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011, 343:d6891.
45. Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010, 51:1972-1978.
46. Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010, 59:1279-1287.
47. Bugianesi E., Salamone F., Negro F. The interaction of metabolic factors with HCV infection: does it matter?. J Hepatol 2012, 56(Suppl 1):S56-S65.
48. Wong V.W., Wong G.L., Chu W.C., Chim A.M., Ong A., Yeung D.K., et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 2012, 56:533-540.
49. Jan C.F., Chen C.J., Chiu Y.H., Chen L.S., Wu H.M., Huang C.C., et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung community-based integrated screening study No. 10). Int J Obes (Lond) 2006, 30:794-799.
50. Wong F., Raina N., Richardson R. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment. Gut 2010, 59:381-386.
51. Lai M.S., Hsieh M.S., Chiu Y.H., Chen T.H. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006, 43:1295-1302.
52. Chen C.L., Yang H.I., Yang W.S., Liu C.J., Chen P.J., You S.L., et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008, 135:111-121.
53. Hassan M.M., Hwang L.Y., Hatten C.J., Swaim M., Li D., Abbruzzese J.L., et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002, 36:1206-1213.
54. Veldt B.J., Chen W., Heathcote E.J., Wedemeyer H., Reichen J., Hofmann W.P., et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47:1856-1862.
55. Caldwell S.H., Crespo D.M., Kang H.S., Al-Osaimi A.M. Obesity and hepatocellular carcinoma. Gastroenterology 2004, 127:S97-S103.
56. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012, 10:1342-1359. e2.
57. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
58. Angulo P., Hui J.M., Marchesini G., Bugianesi E., George J., Farrell G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007, 45:846-854.
59. Wong V.W., Wong G.L., Chim A.M., Tse A.M., Tsang S.W., Hui A.Y., et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol 2008, 103:1682-1688.
60. Wong V.W., Wong G.L., Yan K.K., Chim A.M., Chan H.Y., Tse C.H., et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:1945-1953.
61. Wong V.W., Vergniol J., Wong G.L., Foucher J., Chan A.W., Chermak F., et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2012, 107:1862-1871.
62. Schwimmer J.B., Deutsch R., Kahen T., Lavine J.E., Stanley C., Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006, 118:1388-1393.
63. Feldstein A.E., Charatcharoenwitthaya P., Treeprasertsuk S., Benson J.T., Enders F.B., Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009, 58:1538-1544.
64. Wong V.W., Chan H.L. Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Ann Hepatol 2012, 11:284-293.
65. Yasui K., Hashimoto E., Komorizono Y., Koike K., Arii S., Imai Y., et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011, 9:428-433. quiz e50.
66. Paradis V., Zalinski S., Chelbi E., Guedj N., Degos F., Vilgrain V., et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49:851-859.
67. Torres D.M., Harrison S.A. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. Semin Liver Dis 2012, 32:30-38.
68. Baffy G., Brunt E.M., Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012, 56:1384-1391.
69. Siegel A.B., Zhu A.X. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009, 115:5651-5661.
70. Tanaka S., Wands J.R. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor beta1-induced apoptosis. Cancer Res 1996, 56:3391-3394.
71. Shen C., Zhao C.Y., Zhang R., Qiao L. Obesity-related hepatocellular carcinoma: roles of risk factors altered in obesity. Front Biosci (Landmark Ed) 2012, 17:2356-2370.
72. Siddique A., Kowdley K.V. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 2011, 15:281-296. vii-x.
73. Vinciguerra M., Foti M. PTEN at the crossroad of metabolic diseases and cancer in the liver. Ann Hepatol 2008, 7:192-199.
74. Stiles B., Wang Y., Stahl A., Bassilian S., Lee W.P., Kim Y.J., et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc Natl Acad Sci U S A 2004, 101:2082-2087.
75. Horie Y., Suzuki A., Kataoka E., Sasaki T., Hamada K., Sasaki J., et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 2004, 113:1774-1783.
76. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012, 142:711-725. e6.
77. Sun B., Karin M. Obesity, inflammation, and liver cancer. J Hepatol 2012, 56:704-713.
78. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
79. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
80. Toffanin S., Friedman S.L., Llovet J.M. Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link. Cancer Cell 2010, 17:115-117.
81. Angulo P., Alba L.M., Petrovic L.M., Adams L.A., Lindor K.D., Jensen M.D. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004, 41:943-949.
82. Shen J., Sakaida I., Uchida K., Terai S., Okita K. Leptin enhances TNF-alpha production via p38 and JNK MAPK in LPS-stimulated Kupffer cells. Life Sci 2005, 77:1502-1515.
83. Aleffi S., Petrai I., Bertolani C., Parola M., Colombatto S., Novo E., et al. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology 2005, 42:1339-1348.
84. Ahima R.S., Osei S.Y. Leptin signaling. Physiol Behav 2004, 81:223-241.
85. Saxena N.K., Sharma D., Ding X., Lin S., Marra F., Merlin D., et al. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 2007, 67:2497-2507.
86. Kaser S., Moschen A., Cayon A., Kaser A., Crespo J., Pons-Romero F., et al. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005, 54:117-121.
87. Yamauchi T., Kadowaki T. Adiponectin receptor as a key player in healthy longevity and obesity-related diseases. Cell Metab 2013, 17:185-196.
88. Thakur V., Pritchard M.T., McMullen M.R., Nagy L.E. Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol 2006, 290:G998-G1007.
89. Awazawa M., Ueki K., Inabe K., Yamauchi T., Kaneko K., Okazaki Y., et al. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochem Biophys Res Commun 2009, 382:51-56.
90. Mihaylova M.M., Shaw R.J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011, 13:1016-1023.
91. Awazawa M., Ueki K., Inabe K., Yamauchi T., Kubota N., Kaneko K., et al. Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 2011, 13:401-412.
92. Sharma D., Wang J., Fu P.P., Sharma S., Nagalingam A., Mells J., et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 2010, 52:1713-1722.
93. Saxena N.K., Fu P.P., Nagalingam A., Wang J., Handy J., Cohen C., et al. Adiponectin modulates C-jun N-terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology 2010, 139:1762-1773. 73 e1-5.
94. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8:286-298.
95. Klose R.J., Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 2006, 31:89-97.
96. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008, 40:741-750.
97. Tsang D.P., Cheng A.S. Epigenetic regulation of signaling pathways in cancer: role of the histone methyltransferase EZH2. J Gastroenterol Hepatol 2011, 26:19-27.
98. Shinkai Y., Tachibana M. H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev 2011, 25:781-788.
99. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007, 39:237-242.
100. Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M., Zimmerman J., et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007, 39:232-236.
101. Calvisi D.F., Ladu S., Gorden A., Farina M., Lee J.S., Conner E.A., et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007, 117:2713-2722.
102. Kondo Y., Shen L., Suzuki S., Kurokawa T., Masuko K., Tanaka Y., et al. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol Res 2007, 37:974-983.
103. Cheng A.S., Lau S.S., Chen Y., Kondo Y., Li M.S., Feng H., et al. EZH2-mediated concordant repression of Wnt antagonists promotes beta-catenin-dependent hepatocarcinogenesis. Cancer Res 2011, 71:4028-4039.
104. Kirsch R., Clarkson V., Shephard E.G., Marais D.A., Jaffer M.A., Woodburne V.E., et al. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J Gastroenterol Hepatol 2003, 18:1272-1282.
105. Pogribny I.P., Tryndyak V.P., Bagnyukova T.V., Melnyk S., Montgomery B., Ross S.A., et al. Hepatic epigenetic phenotype predetermines individual susceptibility to hepatic steatosis in mice fed a lipogenic methyl-deficient diet. J Hepatol 2009, 51:176-186.
106. Tryndyak V.P., Han T., Muskhelishvili L., Fuscoe J.C., Ross S.A., Beland F.A., et al. Coupling global methylation and gene expression profiles reveal key pathophysiological events in liver injury induced by a methyl-deficient diet. Mol Nutr Food Res 2011, 55:411-418.
107. Jun H.J., Kim J., Hoang M.H., Lee S.J. Hepatic lipid accumulation alters global histone h3 lysine 9 and 4 trimethylation in the peroxisome proliferator-activated receptor alpha network. PLoS One 2012, 7:e44345.
108. Pirola C.J., Gianotti T.F., Burgueno A.L., Rey-Funes M., Loidl C.F., Mallardi P., et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013, 62:1356-1363.
109. Sookoian S., Rosselli M.S., Gemma C., Burgueno A.L., Fernandez Gianotti T., Castano G.O., et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology 2010, 52:1992-2000.
110. Ahrens M., Ammerpohl O., von Schonfels W., Kolarova J., Bens S., Itzel T., et al. DNA methylation analysis in nonalcoholic Fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 2013, 18:296-302.
111. Rabl C., Campos G.M. The impact of bariatric surgery on nonalcoholic steatohepatitis. Semin Liver Dis 2012, 32:80-91.
112. Murphy S.K., Yang H., Moylan C.A., Pang H., Dellinger A., Abdelmalek M.F., et al. Relationship between the methylome and transcriptome in patients with non-alcoholic fatty liver disease. Gastroenterology 2013, (in press).
113. Mato J.M., Lu S.C. Role of S-adenosyl-l-methionine in liver health and injury. Hepatology 2007, 45:1306-1312.
114. Lu S.C., Alvarez L., Huang Z.Z., Chen L., An W., Corrales F.J., et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc Natl Acad Sci U S A 2001, 98:5560-5565.
115. Martinez-Chantar M.L., Corrales F.J., Martinez-Cruz L.A., Garcia-Trevijano E.R., Huang Z.Z., Chen L., et al. Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J 2002, 16:1292-1294.
116. Yang H., Cho M.E., Li T.W., Peng H., Ko K.S., Mato J.M., et al. MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest 2013, 123:285-298.
117. Martinez-Chantar M.L., Vazquez-Chantada M., Ariz U., Martinez N., Varela M., Luka Z., et al. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 2008, 47:1191-1199.
118. Liao Y.J., Liu S.P., Lee C.M., Yen C.H., Chuang P.C., Chen C.Y., et al. Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: Implications of the gender disparity in liver cancer susceptibility. Int J Cancer 2009, 124:816-826.
119. Martinez-Una M., Varela-Rey M., Cano A., Fernandez-Ares L., Beraza N., Aurrekoetxea I., et al. Excess S-adenosylmethionine reroutes phosphatidylethanolamine towards phosphatidylcholine and triglyceride synthesis. Hepatology 2013, (in press).
120. Lu S.C., Mato J.M. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev 2012, 92:1515-1542.
121. Martinez-Lopez N., Garcia-Rodriguez J.L., Varela-Rey M., Gutierrez V., Fernandez-Ramos D., Beraza N., et al. Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1. Gastroenterology 2012, 143:787-798. e1-13.
122. Frau M., Feo F., Pascale R.M. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. J Hepatol 2013, (in press).
123. Lu S.C., Ramani K., Ou X., Lin M., Yu V., Ko K., et al. S-adenosylmethionine in the chemoprevention and treatment of hepatocellular carcinoma in a rat model. Hepatology 2009, 50:462-471.
124. Frau M., Tomasi M.L., Simile M.M., Demartis M.I., Salis F., Latte G., et al. Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. Hepatology 2012, 56:165-175.
125. Huidobro C., Torano E.G., Fernandez A.F., Urdinguio R.G., Rodriguez R.M., Ferrero C., et al. A DNA methylation signature associated with the epigenetic repression of glycine N-methyltransferase in human hepatocellular carcinoma. J Mol Med (Berl) 2013, 91:939-950.
126. Chan H.M., La Thangue N.B. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001, 114:2363-2373.
127. Wellen K.E., Hatzivassiliou G., Sachdeva U.M., Bui T.V., Cross J.R., Thompson C.B. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009, 324:1076-1080.
128. Denechaud P.D., Dentin R., Girard J., Postic C. Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett 2008, 582:68-73.
129. Bricambert J., Miranda J., Benhamed F., Girard J., Postic C., Dentin R. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest 2010, 120:4316-4331.
130. Li M., Luo R.Z., Chen J.W., Cao Y., Lu J.B., He J.H., et al. High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma. J Transl Med 2011, 9:5.
131. Alenghat T., Meyers K., Mullican S.E., Leitner K., Adeniji-Adele A., Avila J., et al. Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 2008, 456:997-1000.
132. Feng D., Liu T., Sun Z., Bugge A., Mullican S.E., Alenghat T., et al. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 2011, 331:1315-1319.
133. Sun Z., Miller R.A., Patel R.T., Chen J., Dhir R., Wang H., et al. Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med 2012, 18:934-942.
134. Bhaskara S., Knutson S.K., Jiang G., Chandrasekharan M.B., Wilson A.J., Zheng S., et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 2010, 18:436-447.
135. You S.H., Lim H.W., Sun Z., Broache M., Won K.J., Lazar M.A. Nuclear receptor co-repressors are required for the histone-deacetylase activity of HDAC3 in vivo. Nat Struct Mol Biol 2013, 20:182-187.
136. Colak Y., Ozturk O., Senates E., Tuncer I., Yorulmaz E., Adali G., et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit 2011, 17:HY5-HY9.
137. Herranz D., Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer 2010, 10:819-823.
138. Pfluger P.T., Herranz D., Velasco-Miguel S., Serrano M., Tschop M.H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A 2008, 105:9793-9798.
139. Banks A.S., Kon N., Knight C., Matsumoto M., Gutierrez-Juarez R., Rossetti L., et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 2008, 8:333-341.
140. Escande C., Chini C.C., Nin V., Dykhouse K.M., Novak C.M., Levine J., et al. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice. J Clin Invest 2010, 120:545-558.
141. Purushotham A., Schug T.T., Xu Q., Surapureddi S., Guo X., Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 2009, 9:327-338.
142. Sun C., Zhang F., Ge X., Yan T., Chen X., Shi X., et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007, 6:307-319.
143. Oberdoerffer P., Michan S., McVay M., Mostoslavsky R., Vann J., Park S.K., et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008, 135:907-918.
144. Palacios J.A., Herranz D., De Bonis M.L., Velasco S., Serrano M., Blasco M.A. SIRT1 contributes to telomere maintenance and augments global homologous recombination. J Cell Biol 2010, 191:1299-1313.
145. Wang R.H., Li C., Deng C.X. Liver steatosis and increased ChREBP expression in mice carrying a liver specific SIRT1 null mutation under a normal feeding condition. Int J Biol Sci 2010, 6:682-690.
146. Suter M.A., Chen A., Burdine M.S., Choudhury M., Harris R.A., Lane R.H., et al. A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates. FASEB J 2012, 26:5106-5114.
147. Wang R.H., Sengupta K., Li C., Kim H.S., Cao L., Xiao C., et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008, 14:312-323.
148. Herranz D., Munoz-Martin M., Canamero M., Mulero F., Martinez-Pastor B., Fernandez-Capetillo O., et al. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun 2010, 1:3.
149. Beauharnois J.M., Bolivar B.E., Welch J.T. Sirtuin 6: a review of biological effects and potential therapeutic properties. Mol Biosyst 2013, 9:1789-1806.
150. Kim H.S., Xiao C., Wang R.H., Lahusen T., Xu X., Vassilopoulos A., et al. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab 2010, 12:224-236.
151. Moschen A.R., Wieser V., Gerner R.R., Bichler A., Enrich B., Moser P., et al. Adipose tissue and liver expression of SIRT1, 3 and 6 increase after extensive weight loss in morbid obesity. J Hepatol 2013, (in press).
152. Marquardt J.U., Fischer K., Baus K., Kashyap A., Ma S., Krupp M., et al. Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology 2013, 58:1054-1064.
153. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
154. Rottiers V., Naar A.M. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012, 13:239-250.
155. Rayner K.J., Esau C.C., Hussain F.N., McDaniel A.L., Marshall S.M., van Gils J.M., et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011, 478:404-407.
156. Jordan S.D., Kruger M., Willmes D.M., Redemann N., Wunderlich F.T., Bronneke H.S., et al. Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011, 13:434-446.
157. Trajkovski M., Hausser J., Soutschek J., Bhat B., Akin A., Zavolan M., et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011, 474:649-653.
158. Kornfeld J.W., Baitzel C., Konner A.C., Nicholls H.T., Vogt M.C., Herrmanns K., et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature 2013, 494:111-115.
159. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
160. Wang X.W., Heegaard N.H., Orum H. MicroRNAs in liver disease. Gastroenterology 2012, 142:1431-1443.
161. Cheung O., Puri P., Eicken C., Contos M.J., Mirshahi F., Maher J.W., et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008, 48:1810-1820.
162. Hou J., Lin L., Zhou W., Wang Z., Ding G., Dong Q., et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011, 19:232-243.
163. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
164. Esau C., Davis S., Murray S.F., Yu X.X., Pandey S.K., Pear M., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006, 3:87-98.
165. Thomas M., Deiters A. MicroRNA miR-122 as a therapeutic target for oligonucleotides and small molecules. Curr Med Chem 2013, 20:3629-3640.
166. Hsu S.H., Wang B., Kota J., Yu J., Costinean S., Kutay H., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012, 122:2871-2883.
167. Tsai W.C., Hsu S.D., Hsu C.S., Lai T.C., Chen S.J., Shen R., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012, 122:2884-2897.
168. Zeisel M.B., Pfeffer S., Baumert T.F. miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. J Hepatol 2013, 58:821-823.
169. Tsai W.C., Hsu P.W., Lai T.C., Chau G.Y., Lin C.W., Chen C.M., et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009, 49:1571-1582.
170. Denda A., Kitayama W., Kishida H., Murata N., Tsutsumi M., Tsujiuchi T., et al. Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, l-amino acid-defined diet. Jpn J Cancer Res 2002, 93:125-132.
171. Nakae D., Yoshiji H., Mizumoto Y., Horiguchi K., Shiraiwa K., Tamura K., et al. High incidence of hepatocellular carcinomas induced by a choline deficient l-amino acid defined diet in rats. Cancer Res 1992, 52:5042-5045.
172. Wang B., Majumder S., Nuovo G., Kutay H., Volinia S., Patel T., et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009, 50:1152-1161.
173. Vinciguerra M., Sgroi A., Veyrat-Durebex C., Rubbia-Brandt L., Buhler L.H., Foti M. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009, 49:1176-1184.
174. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S.T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133:647-658.
175. Wang B., Hsu S.H., Frankel W., Ghoshal K., Jacob S.T. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 2012, 56:186-197.
176. Inoue H., Ogawa W., Ozaki M., Haga S., Matsumoto M., Furukawa K., et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 2004, 10:168-174.
177. Gallagher I.J., Scheele C., Keller P., Nielsen A.R., Remenyi J., Fischer C.P., et al. Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med 2010, 2:9.
178. Xie H., Lim B., Lodish H.F. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes 2009, 58:1050-1057.
179. Takanabe R., Ono K., Abe Y., Takaya T., Horie T., Wada H., et al. Up-regulated expression of microRNA-143 in association with obesity in adipose tissue of mice fed high-fat diet. Biochem Biophys Res Commun 2008, 376:728-732.
180. Zhang X., Liu S., Hu T., He Y., Sun S. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression. Hepatology 2009, 50:490-499.
181. Pogribny I.P., Starlard-Davenport A., Tryndyak V.P., Han T., Ross S.A., Rusyn I., et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 2010, 90:1437-1446.
182. Worm J., Stenvang J., Petri A., Frederiksen K.S., Obad S., Elmen J., et al. Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp beta and down-regulation of G-CSF. Nucleic Acids Res 2009, 37:5784-5792.
183. Yan X.L., Jia Y.L., Chen L., Zeng Q., Zhou J.N., Fu C.J., et al. Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology 2013, 57:2274-2286.
184. Zelber-Sagi S., Nitzan-Kaluski D., Halpern Z., Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006, 26:856-863.
185. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Blendis L., Halpern Z., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007, 47:711-717.
186. Pan S.Y., Johnson K.C., Ugnat A.M., Wen S.W., Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol 2004, 159:259-268.
187. Kuriyama S., Tsubono Y., Hozawa A., Shimazu T., Suzuki Y., Koizumi Y., et al. Obesity and risk of cancer in Japan. Int J Cancer 2005, 113:148-157.
188. Jee S.H., Yun J.E., Park E.J., Cho E.R., Park I.S., Sull J.W., et al. Body mass index and cancer risk in Korean men and women. Int J Cancer 2008, 123:1892-1896.
189. Wideroff L., Gridley G., Mellemkjaer L., Chow W.H., Linet M., Keehn S., et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997, 89:1360-1365.
190. Jee S.H., Ohrr H., Sull J.W., Yun J.E., Ji M., Samet J.M. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005, 293:194-202.
191. Chen H.F., Chen P., Li C.Y. Risk of malignant neoplasms of liver and biliary tract in diabetic patients with different age and sex stratifications. Hepatology 2010, 52:155-163.
192. Zhang P.H., Chen Z.W., Lv D., Xu Y.Y., Gu W.L., Zhang X.H., et al. Increased risk of cancer in patients with type 2 diabetes mellitus: a retrospective cohort study in China. BMC Pub Health 2012, 12:567.
193. Ruggieri A., Barbati C., Malorni W. Cellular and molecular mechanisms involved in hepatocellular carcinoma gender disparity. Int J Cancer 2010, 127:499-504.
194. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
195. Yang W., Lu Y., Xu Y., Xu L., Zheng W., Wu Y., et al. Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem 2012, 287:40140-40149.
196. Yamagata Y., Asada H., Tamura I., Lee L., Maekawa R., Taniguchi K., et al. DNA methyltransferase expression in the human endometrium: down-regulation by progesterone and estrogen. Hum Reprod 2009, 24:1126-1132.
197. Li Y., Liu L., Andrews L.G., Tollefsbol T.O. Genistein depletes telomerase activity through cross-talk between genetic and epigenetic mechanisms. Int J Cancer 2009, 125:286-296.
198. Li H., Xu W., Huang Y., Huang X., Xu L., Lv Z. Genistein demethylates the promoter of CHD5 and inhibits neuroblastoma growth in vivo. Int J Mol Med 2012, 30:1081-1086.
199. Cha T.L., Zhou B.P., Xia W., Wu Y., Yang C.C., Chen C.T., et al. Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science 2005, 310:306-310.
200. Bredfeldt T.G., Greathouse K.L., Safe S.H., Hung M.C., Bedford M.T., Walker C.L. Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. Mol Endocrinol 2010, 24:993-1006.
201. Greathouse K.L., Bredfeldt T., Everitt J.I., Lin K., Berry T., Kannan K., et al. Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis. Mol Cancer Res 2012, 10:546-557.
202. Wong R.L., Walker C.L. Molecular pathways: environmental estrogens activate nongenomic signaling to developmentally reprogram the epigenome. Clin Cancer Res 2013, 19:3732-3737.
203. Xu K., Wu Z.J., Groner A.C., He H.H., Cai C., Lis R.T., et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science 2012, 338:1465-1469.
204. Kim E., Kim M., Woo D.H., Shin Y., Shin J., Chang N., et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013, 23:839-852.
205. Ma W.L., Hsu C.L., Wu M.H., Wu C.T., Wu C.C., Lai J.J., et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology 2008, 135:947-955. 55 e1-5.
206. Wu M.H., Ma W.L., Hsu C.L., Chen Y.L., Ou J.H., Ryan C.K., et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med 2010, 2:32ra5.
207. Feng H., Cheng A.S., Tsang D.P., Li M.S., Go M.Y., Cheung Y.S., et al. Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin/T cell factor-dependent hepatocarcinogenesis. J Clin Invest 2011, 121:3159-3175.
208. Chen P.J., Yeh S.H., Liu W.H., Lin C.C., Huang H.C., Chen C.L., et al. Androgen pathway stimulates microRNA-216a transcription to suppress the tumor suppressor in lung cancer-1 gene in early hepatocarcinogenesis. Hepatology 2012, 56:632-643.
209. Cao Y., Xue Y., Xue L., Jiang X., Wang X., Zhang Z., et al. Hepatic menin recruits SIRT1 to control liver steatosis through histone deacetylation. J Hepatol 2013, (in press).
210. Moore R.L., Dai Y., Faller D.V. Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol 2012, 213:37-48.
211. Dai Y., Ngo D., Forman L.W., Qin D.C., Jacob J., Faller D.V. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol 2007, 21:1807-1821.
212. Chng K.R., Chang C.W., Tan S.K., Yang C., Hong S.Z., Sng N.Y., et al. A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. Embo J 2012, 31:2810-2823.
213. Tessel M.A., Krett N.L., Rosen S.T. Steroid receptor and microRNA regulation in cancer. Curr Opin Oncol 2010, 22:592-597.
214. Guttilla I.K., Adams B.D., White B.A. ERalpha, microRNAs, and the epithelial-mesenchymal transition in breast cancer. Trends Endocrinol Metab 2012, 23:73-82.
215. Ribas J., Ni X., Haffner M., Wentzel E.A., Salmasi A.H., Chowdhury W.H., et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009, 69:7165-7169.
216. Saumet A., Vetter G., Bouttier M., Antoine E., Roubert C., Orsetti B., et al. Estrogen and retinoic acid antagonistically regulate several microRNA genes to control aerobic glycolysis in breast cancer cells. Mol Biosyst 2012, 8:3242-3253.
217. Yu X., Zhang X., Dhakal I.B., Beggs M., Kadlubar S., Luo D. Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. BMC Cancer 2012, 12:29.
218. Yu Z., Cheng A.S. Epigenetic deregulation of microRNAs: new opportunities to target oncogenic signaling pathways in hepatocellular carcinoma. Curr Pharm Des 2013, 19:1192-1200.
219. Bai A.H., Cheng A.S. Alliance of epigenetic forces for the activation of oncogenic Wnt/beta-catenin signaling. J Gastroenterol Hepatol 2013, 28:383-385.
220. Baylin S.B., Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction. Nat Rev Cancer 2006, 6:107-116.
221. Chiba T., Marusawa H., Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012, 143:550-563.
222. Tian W., Xu H., Fang F., Chen Q., Xu Y., Shen A. Brahma-related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice. Hepatology 2013, 58:576-588.
223. Teufel A., Marquardt J.U., Galle P.R. Next generation sequencing of HCC from European and Asian HCC cohorts. Back to p53 and Wnt/beta-catenin. J Hepatol 2013, 58:622-624.
224. Villanueva A., Minguez B., Forner A., Reig M., Llovet J.M. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010, 61:317-328.
225. Hsu S.H., Yu B., Wang X., Lu Y., Schmidt C.R., Lee R.J., et al. Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine 2013, (in press).
226. Yeo W., Chung H.C., Chan S.L., Wang L.Z., Lim R., Picus J., et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012, 30:3361-3367.
227. Ross S.A., Milner J.A. Epigenetic modulation and cancer: effect of metabolic syndrome. Am J Clin Nutr 2007, 86:s872-s877.
228. Goldsworthy M., Absalom N.L., Schroter D., Matthews H.C., Bogani D., Moir L., et al. Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice. PLoS One 2013, 8:e61870.
229. Rappa F., Greco A., Podrini C., Cappello F., Foti M., Bourgoin L., et al. Correction: immunopositivity for histone MacroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma. PLoS One 2013, 8.
230. Yoshimoto S., Loo T.M., Atarashi K., Kanda H., Sato S., Oyadomari S., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.
231. Lee J.S., Kim J.H., Park Y.Y., Mills G.B. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 2011, 43:205-211.
232. Sookoian S., Pirola C.J. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS One 2013, 8:e58895.